CONTRAINDICATIONS

- Hypersensitivity to any component of the medication.- Severe renal impairment (CLcr < 30 ml/min).- [HYPERCALCEMIA] or conditions causing hypercalcemia- History of [HYPOPHOSPHATEMIA]- Nephrolithiasis due to calcium [KIDNEY STONES].

PREGNANCY

An open-label, controlled study in 281 pregnant women demonstrated no significant adverse effects of Gaviscon on the course of pregnancy or the health of the fetus/newborn child. Based on this and previous experience, this medicine can be used during pregnancy. However, given the presence of calcium carbonate, it is recommended to limit the duration of treatment as much as possible and avoid concomitant intake of milk and dairy products to prevent calcium excess, which can trigger milk-alkali syndrome.

INDICATIONS

- Symptomatic treatment of [GASTRIC HYPERACIDITY] and heartburn caused by acid reflux from the stomach.

INTERACTIONS

- Digitalis (digoxin, digitoxin): there are studies with some antacids (algeldrate, magnesium hydroxide) in which a decrease in the absorption of digitalis has been recorded, so it is recommended to space its administration 2 or 3 hours apart.
- Erlotinib: Possible reduction in erlotinib levels due to reduced absorption. Antacids increase gastric pH, which could decrease erlotinib solubility, absorption, and therapeutic effects. It is recommended to administer at least 4 hours before or 2 hours after the daily dose of the antineoplastic agent.
- Gabapentin: Some decreases in gabapentin levels have been observed when administered concomitantly with or within 2 hours of taking other antacids, due to increased pH. It is recommended that gabapentin be administered 2 hours before an antacid.
- Quinolones (ciprofloxacin, norfloxacin): there are studies with some antacids (algeldrate, almagate) in which a decrease in their absorption has been recorded due to the formation of insoluble, non-absorbable complexes at the intestinal level, so it is recommended to separate their administration by 2 or 3 hours.
- Iron salts (citrate, fumarate, iron sulfate): there are studies with some antacids (algeldrate, magnesium trisilicate) in which a decrease in absorption has been recorded due to the formation of poorly soluble complexes, so it is recommended to space administration by 2 or 3 hours.
- Lithium salts (lithium carbonate): Studies have shown a possible increase in its renal excretion with loss of antimanic activity, due to the fact that some of the sodium may be reabsorbed instead of lithium.
- Tetracyclines (tetracycline): there are studies in which the possible formation of non-absorbable complexes at the gastrointestinal level has been recorded, thus decreasing their absorption, so it is recommended to space administration by 2 or 3 hours.

LACTATION

Accepted use. Chronic or excessive use is not recommended.

RULES FOR CORRECT ADMINISTRATION

- Oral administration, preferably after meals and before going to bed.

- It should not be taken with large amounts of milk or dairy products since (due to its calcium antacid content) it can cause increased blood calcium levels and milk-alkali syndrome (Burnett syndrome).

- Separate the administration of this medication from any other drug.

POSOLOGY

- Adults and children 12 years and older (normal and forte), oral: 2-4 chewable tablets or 1-2 sachets, as needed, up to 4 times a day; maximum 16 tablets/day or 8 sachets/day.

- Children < 12 years: not recommended, unless otherwise indicated by a medical professional.

As with all antacids, if symptoms persist for more than 7 days despite continued treatment, the clinical situation should be evaluated.

PRECAUTIONS

- [KIDNEY STONES]. Avoid prolonged use because it increases the risk of developing kidney stones.
- [HYPERCALCEMIA]. Administration of high doses over long periods of time may produce undesirable effects such as hypercalcemia and milk-alkali syndrome, especially in patients with renal impairment. The drug should not be administered with large amounts of milk or dairy products.
- [HYPERCALCIURIA]. It should not be administered to these patients.
- [RENAL FAILURE]. Administration is not recommended in patients with severe renal impairment (CrCl <30 ml/min). If administered for a long time with CrCl >/= 30 ml/min, plasma levels of calcium, phosphate and magnesium should be monitored regularly.
- In general, calcium-containing antacids should not be given to patients with [CONSTIPATION], [HEMORRHOIDS] and [SARCOIDOSIS], unless otherwise determined by a medical professional.
- Patients with very low gastric acid levels. There is a possibility of reduced efficacy in these patients.
- Isolated cases of a possible relationship between calcium carbonate, [APPENDICITIS], [GASTROINTESTINAL HEMORRHAGE], [INTESTINAL OBSTRUCTION], or [EDEMA] have been described in the literature.

PRECAUTIONS RELATED TO EXCIPIENTS

- This medicine contains aspartame as an excipient, so it should be taken into account by people suffering from [PHENYLKETONURIA]. 100 mg of aspartame corresponds to 56.13 mg of phenylalanine.

ADVERSE REACTIONS

- Exceptionally, allergic reactions such as [URTICARIA] or [BRONCHIAL SPASM] and [ANAPHYLAXIS] have been observed.
- Metabolism and nutrition disorders such as [HYPERCALCEMIA] and [ALKALOSIS] as well as Burnett's syndrome (milk-alkali syndrome) have also been reported due to prolonged use and high doses.